<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134445">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845779</url>
  </required_header>
  <id_info>
    <org_study_id>Epitope-HPV01</org_study_id>
    <nct_id>NCT01845779</nct_id>
  </id_info>
  <brief_title>Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal</brief_title>
  <acronym>Epitopes-HPV01</acronym>
  <official_title>Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Person</authority>
    <authority>France: French Health Products Safety Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complete response is a rare event in metastatic anal cancer in the case of unresectable
      recurrence after radiochemotherapy.

      In the University Hospital Center of Besançon, 8 patients with metastatic anal cancer were
      treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: DCF (Docetaxel,
      Cisplatin and 5-Fluorouracil.

      In more than 90% of cases, anal cancers are related to Human Papilloma Virus (HPV)
      infection, that is the case of this patients for which HPV16 (human papillomavirus type 16)
      genotype   was identified within the tumor samples.

      The hypothesis is that an anti-HPV response immune could be generated by chemotherapy with
      DCF and contributed to the elimination of the tumour cells and to the increase of complete
      responses. The aim to this study is to analyze immune response against HPV in this patients
      in complete response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>presence and characterization of anti-HPV immune responses in patients in complete remission</measure>
    <time_frame>3 months after sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>global survival</measure>
    <time_frame>from date to initiation of chemotherapy until the date of death for any cause assessed up to 100 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>from date to initiation of chemotherapy until the date of first documented progression, assessed up to 60 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Metastatic Anal Canal Cancer</condition>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>patients in complete response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCF regimen</intervention_name>
    <arm_group_label>patients in complete response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status ≤ 1

          -  patient with metastatic anal cancer HPV+

          -  presence of a measurable target lesion according to radiological criteria (Recist
             V1.1)

          -  patient with more than 12 months of complete remission of metastatic anal cancer
             according to radiological criteria (Recist V1.1)after treatment by DCF regimen
             (Docetaxel, Cisplatin and 5-Fluorouracil)

        Exclusion Criteria:

          -  pregnancy or lactation

          -  patient with any medical or psychiatric condition or disease which would make the
             patient inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe BORG, Prof</last_name>
    <phone>+3381615615</phone>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion JACQUIN</last_name>
    <email>m1jacquin@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Oncology - University Hospital of Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BORG, Prof</last_name>
      <phone>+3381615615</phone>
      <email>christophe.borg@efs.sante.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion JACQUIN</last_name>
      <email>m1jacquin@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe BORG, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François BOSSET, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Nguyen, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
